Table 1 Clinical characteristics of the study population
HGSOC (n=28) | |
|---|---|
Age at diagnosis | 62.2 ± 9.5 |
BMI (Kg/m2) | 23.5 ± 2.7 |
Previous cancer | 2 (7.1%) |
Breast cancer | 1 (50%) |
Gastrointestinal Stromal Tumors | 1 (50%) |
Thyroid cancer | 0 (0%) |
Comorbidity | |
Hypertension | 7 (25%) |
Hypercholesterolemia | 4 (14.3%) |
Hypertrigliceridemia | 2 (7.1%) |
Heart disease | 1 (3.6%) |
Depression | 1 (3.6%) |
Diabetes mellitus | 2 (7.1%) |
BRCA 1 mut | 6 (21.4%) |
BRCA 2 mut | 6 (21.4%) |
BRCA wt | 16 (57.2%) |
Surgery | 19 (67.9%) |
PDS | 8 (28.6%) |
IDS | 11 (39.3%) |
TR | 4 (14.3%) |
≤ 1 cm | 3 (75%) |
> 1 cm | 1 (25%) |
Fist line chemotherapy | |
Carboplatin+Taxol | 14 (50%) |
Carboplatin+Taxol+Bevacizumab | 10 (35.7%) |
Carboplatin+Taxol+Gemcitabin+Bevacizumab | 4 (14.3%) |
Maintenance therapy | 20 (71.4%) |
Niraparib | 2 (10%) |
Bevacizumab | 6 (30%) |
Olaparib | 5 (25%) |
Bevacizumab+Olaparib | 2 (10%) |
Others | 5 (25%) |
FIGO stage | |
IIIC | 20 (71.4%) |
IVA | 3 (10.7%) |
IVB | 5 (17.9%) |
Prognosis | |
Recurrence | 24 (85.7%) |
PFI (months) | 12.5 ± 10.9 |
DFS (months) | 25.8 ± 15.2 |
OS (months) | 39.9 ± 19.4 |